Close Menu

MDxHealth

NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services finalized a coverage policy to begin reimbursing MDxHealth's ConfirmMDx prostate cancer test effective Nov. 3.

NEW YORK (GenomeWeb) – MDxHealth today reported that its revenues for the first half of 2014 increased 20 percent over the first half of 2013, driven by sales of its ConfirmMDx prostate cancer test.

NEW YORK (GenomeWeb) – Researchers from Johns Hopkins University have published data from an independent validation study in The Journal of Urology reporting that increased methylation of GSTP

NEW YORK (GenomeWeb) – MDxHealth today announced the signing of agreements that increase the number of covered lives with access to its ConfirmMDx for Prostate Cancer test to more than 152 million in the US.

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued draft local coverage determinations stipulating reimbursement criteria for three multi-marker molecular diagnostics: Assurex Health's pharmacogenetic test for refractory depression, MDxHealth's ConfirmMDx epigenetic prostate cance

NEW YORK (GenomeWeb) – MDxHealth today announced a deal with Miraca Life Sciences to promote MDxHealth's ConfirmMDx Prostate Cancer test.

Genomic Health Publishes Development, Validation Studies on Oncotype DX Prostate Cancer Dx
Genomic Health has published in European Urology data from three studies involving its 17-gene Oncotype DX prostate cancer test.

NEW YORK (GenomeWeb) – MDxHealth said today that American Pathology Partners will promote and co-market the firm's ConfirmMDx for Prostate Cancer test in the US.

NEW YORK (GenomeWeb) – MDxHealth today reported a 36 percent year-over-year increase in its first quarter revenues as sales of its prostate cancer test grew nearly five-fold.

NEW YORK (GenomeWeb) – MDxHealth today announced an agreement with preferred provider organization Galaxy Health Network to provide access to MDxHealth's ConfirmMDx for Prostate Cancer test.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.